« — Four-year mean follow-up data demonstrate an overall response rate (ORR) of over 80% throughout the follow-up period —
— Randomized, double-blind Phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients (GIV-IN PV TRIAL) with over 100 participating international clinical sites to be initiated by mid-2021 —«